What is the detailed management of acute bronchitis in an adult according to the European Respiratory Society guidelines?

Management of Adult Acute Bronchitis According to European Respiratory Society Guidelines

Initial Assessment and Diagnosis

Acute bronchitis is primarily a clinical diagnosis characterized by acute cough with or without sputum production, often accompanied by low-grade fever, muscle aches, fatigue, and bilateral rhonchi on examination. 1, 2

Key Diagnostic Criteria:

• Cough is the cardinal symptom and may be productive or non-productive 1, 2
• Low-grade fever, when present, does not require specific temperature thresholds for diagnosis 2
• Bilateral rhonchi on auscultation are characteristic 2
• Duration of cough typically 2-3 weeks 3
• No focal chest signs, which would suggest pneumonia 1

Differentiation from Pneumonia:

Suspect pneumonia rather than simple bronchitis when: 1

• Fever persisting >4 days 1, 4
• New focal chest signs on examination 1, 4
• Dyspnea or tachypnea (respiratory rate >30 breaths/min) 1
• Temperature <35°C or ≥40°C 1
• Heart rate ≥125 beats/min 1
• Confusion or altered mental status 1

Investigations

Patients WITHOUT Risk Factors:

No investigations are recommended for uncomplicated acute bronchitis in patients without risk factors. 1, 3

• No chest radiography required 1, 3
• No sputum examination needed 1
• No blood tests indicated 1
• No C-reactive protein measurement 1

Patients WITH Risk Factors or Suspected Pneumonia:

Consider investigations when: 1

• Risk factors for severity present (see below) 1
• Focal chest signs detected 1
• Failure to respond to initial therapy 1

Recommended investigations include: 1

• Blood white cell count and C-reactive protein (to be considered) 1
• Chest radiograph if pneumonia suspected 1
• Sputum examination if focal signs present 1

Risk Stratification

High-Risk Patients Requiring Antibiotic Consideration:

The following patients warrant antibiotic therapy despite having acute bronchitis: 1

• Age >75 years with fever 1
• Cardiac failure 1
• Insulin-dependent diabetes mellitus 1
• Serious neurological disorder (stroke, etc.) 1
• Suspected or definite pneumonia 1
• Selected COPD exacerbations (see below) 1

Additional Risk Factors for Complications:

These factors increase risk of severe disease and unusual organisms: 1

• Age >65 years (increased risk of Streptococcus pneumoniae) 1
• Institutionalized patients 1
• Alcoholism (risk of gram-negative bacilli, Legionella) 1
• COPD, cardiovascular disease, chronic liver or renal failure 1
• Recent hospitalization or antibiotic use 1

Antibiotic Therapy

General Principle:

In uncomplicated acute bronchitis without risk factors, antibiotics are NOT indicated as the illness is self-limiting and predominantly viral. 1, 3

• Antibiotics decrease cough duration by only approximately 0.5 days 3
• Side effects outweigh minimal benefits 1, 3
• Most cases are viral and will not respond to antibiotics 1

When Antibiotics ARE Indicated (High-Risk Patients):

First-line antibiotic choice for home management: 1

• Aminopenicillin (e.g., amoxicillin 500-1000 mg every 8 hours orally) 1

Alternative antibiotics: 1

• Tetracycline (e.g., doxycycline 100 mg every 12 hours) 1
• Oral cephalosporin 1
• Third-generation quinolones (e.g., levofloxacin) 1
• Macrolide (e.g., azithromycin 500 mg day 1, then 250 mg daily for 4 days; or clarithromycin 250-500 mg every 12 hours) 1

Special circumstances requiring alternative antibiotics: 1

• High frequency of beta-lactamase-producing Haemophilus influenzae in the area: Use aminopenicillin + beta-lactamase inhibitor (e.g., amoxicillin-clavulanate 1 g every 8 hours) 1
• Chronic lung disease or recent aminopenicillin failure: Use aminopenicillin + beta-lactamase inhibitor 1
• Young adults during Mycoplasma pneumoniae epidemic: Consider macrolide as first-line 1

Duration of antibiotic therapy: 1

• 5-7 days is the recommended duration 1

Antibiotic Coverage Rationale:

Treatment must always cover Streptococcus pneumoniae, the most common bacterial pathogen. 1

Other frequent organisms include: 1

• Mycoplasma pneumoniae 1
• Moraxella catarrhalis 1
• Haemophilus influenzae 1

Symptomatic Treatment

Cough Management:

For dry, bothersome cough disrupting sleep: 1

• Dextromethorphan is recommended (Grade C1) 1
• Codeine can be prescribed (Grade C1) 1

Cough suppression is NOT logical when: 1

• Patient is producing significant sputum volumes 1
• Productive cough serves to clear bronchial secretions 1

Anti-inflammatory Therapy:

Naproxen can be used to decrease cough severity by reducing inflammatory response. 4

• Provides symptomatic benefit within days 4
• Can be added regardless of antibiotic prescription 4
• Particularly useful when cough interferes with quality of life 4

NOT Recommended Treatments:

The following should NOT be prescribed for acute bronchitis (Grade A1): 1

• Expectorants 1
• Mucolytics 1
• Antihistamines 1
• Inhaled bronchodilators (in uncomplicated cases) 1

These over-the-counter medications lack consistent evidence for benefit. 1

Special Considerations for COPD Exacerbations

Antibiotic treatment in COPD exacerbations is indicated when: 1

• Severe exacerbation with low baseline FEV₁ 1
• Increased dyspnea, sputum volume, AND sputum purulence present 1

The evidence for antibiotics in mild COPD exacerbations in primary care is weak, with conflicting results. 1

Hospital Referral Criteria

Immediate hospital referral is required when ANY of the following are present: 1

Clinical Criteria:

• Temperature <35°C or ≥40°C 1
• Heart rate ≥125 beats/min 1
• Respiratory rate ≥30 breaths/min 1
• Cyanosis 1
• Blood pressure <90/60 mmHg 1
• Confusion, drowsiness, or altered mental status 1
• Chest pain 1

Biological Criteria (if available):

• Leukopenia (<4,000 WBC/mL) or severe leukocytosis (>20,000 WBC/mL) 1
• PaO₂ <60 mmHg or PaCO₂ >50 mmHg on room air 1
• Acidosis (pH <7.3) 1
• Renal impairment (urea >7 mM or creatinine >1.2 mg/dL) 1

Radiological Criteria:

• Multilobar involvement 1
• Pleural effusion or cavitation 1

Social/Compliance Factors:

• Home management impossible due to vomiting, social exclusion, extreme poverty, dependency, or poor compliance likelihood 1

Hospital Management (When Required)

Investigations for Hospitalized Patients:

Routine investigations: 1

• Chest radiograph (PA view; lateral if PA normal and pneumonia suspected) 1
• Peripheral blood white cell count 1
• Serum biochemistry (sodium, potassium, glucose, urea, creatinine) 1
• Arterial blood gases or pulse oximetry 1
• Sputum sampling (after mouth-washing; interpret only with >25 PMNs and <10 squamous cells per high-power field) 1

Additional investigations for specific situations: 1

• Blood cultures if temperature >38°C or pneumonia confirmed 1
• Detection of pneumococcal and Legionella antigens (cost-effective in high-risk patients) 1

Antibiotic Therapy for Hospitalized Patients:

For non-ICU hospital management: 1

• Beta-lactam (e.g., IV amoxicillin 1 g every 6 hours) 1
• OR beta-lactam + beta-lactamase inhibitor (e.g., amoxicillin-clavulanate 1 g every 8 hours orally) 1
• OR new macrolide (e.g., azithromycin 500 mg daily for 3 days or clarithromycin 250-500 mg every 12 hours) 1
• OR second-generation fluoroquinolone (e.g., ciprofloxacin 500 mg every 12 hours or ofloxacin 400 mg every 12 hours) 1

Duration: At least 7 days 1

Severe Cases Requiring ICU:

For life-threatening hypoxemia (SpO₂ ≈80%): 5

• Initiate supplemental oxygen immediately, titrate to SpO₂ ≥90% 5
• Begin broad-spectrum antibiotics: anti-pseudomonal beta-lactam (piperacillin-tazobactam or cefepime) PLUS respiratory fluoroquinolone or azithromycin 5
• Obtain arterial blood gas immediately 5
• Collect blood cultures before antibiotics 5
• Monitor continuously and reassess at 48-72 hours 5

Follow-Up and Monitoring

Outpatient Follow-Up:

Patients should be instructed to: 1

• Return if fever does not resolve within 48 hours 1
• Understand that cough may persist longer than antibiotic treatment duration 1
• Clinical effect of antibiotics should be evident within 3 days 4

Seriously ill patients or elderly with comorbidity should be followed up 2 days after first visit. 4

Productive cough persisting beyond 3 weeks warrants diagnostic reassessment. 4

Hospital Follow-Up:

Assess response at day 5-7 for improvement of symptoms. 1

For hospitalized patients, reassess at 48-72 hours; lack of improvement requires investigation for: 1, 5

• Complications 1
• Resistant organisms 1, 5
• Alternative diagnoses 5

Prevention

Pneumococcal vaccine is indicated for: 1

• Age >65 years 1
• Cardiovascular diseases, pulmonary diseases, diabetes mellitus, alcoholism, liver cirrhosis 1
• Immunosuppression (HIV, chronic renal failure, transplant recipients, hematologic malignancies, asplenia) 1

Influenza vaccine is indicated for: 1

• Age >65 years 1
• Chronic diseases 1
• Healthcare workers 1

NOT recommended: 1

• Prophylactic antibiotics 1
• Routine treatment of upper respiratory tract infections 1
• Oral immunization 1

Common Pitfalls to Avoid

Do not prescribe antibiotics for uncomplicated acute bronchitis in low-risk patients – this exposes patients to unnecessary side effects without meaningful benefit. 1, 3

Do not suppress productive cough – sputum clearance is protective. 1

Do not order chest X-rays routinely – reserve for suspected pneumonia or high-risk patients. 1, 3

Do not forget to adjust chronic disease medications – asthma, COPD, cardiac failure, and diabetes often flare during respiratory infections. 1

Do not use the term "bronchitis" when pneumonia is suspected – describing it as a "chest cold" reduces inappropriate antibiotic expectations. 3

Do not ignore persistence of fever beyond 48 hours on antibiotics – this mandates reassessment. 1, 4